Pharmaceutical Technology
Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.
Pharmaceutical Technology
Biogen plans to pause or terminate investment in most of Apellis' legacy research programmes, while cutting some of its workforce.
Pharmaceutical Technology
Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.